Genitourinary syndrome of menopause in breast cancer survivors:Treatments are available.
Level V
Where this comes from
- Record sourced from PubMed, PMID 30289755.
- Also identified by DOI 10.3949/ccjm.85a.17108.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
When treating the genitourinary syndrome of menopause (GSM) in women with breast cancer or at high risk of breast cancer, clinicians must balance the higher cancer risks associated with hormonal treatments against the severity of GSM symptoms, which can be exacerbated by breast cancer treatments. Options for patients who need hormonal therapy include locally applied estrogens, dehydroepiandrosterone (DHEA), and estrogen receptor agonists/antagonists, which vary in their impact on breast cancer risk.
Medical subject headings
- Breast Neoplasms
- Estrogen Replacement Therapy
- Estrogens
- Female Urogenital Diseases
- Long Term Adverse Effects